USPTO 2015–2025 USPTO PatentsView US Corporation

aTyr Pharma, Inc.

USPTO PatentsView assignee record — 82 granted patents across 10 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).

82
Total patents granted
10
CPC technology areas
13.6
Avg claims per patent
-81%
5-year filing velocity

Portfolio overview

aTyr Pharma, Inc. has been granted 82 US utility patents between 2015 and 2025, placing aTyr Pharma, Inc. at rank #4,364 across all assignees tracked by PlainPatent. This portfolio spans 10 distinct Cooperative Patent Classification (CPC) subclasses, averaging 13.6 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a US Corporation, aTyr Pharma, Inc. is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 36.5/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 13 grants, compared with 69 in the 2015–2019 window — a -81% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. aTyr Pharma, Inc.'s 13.6 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 10 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark aTyr Pharma, Inc. against peers pursuing similar technology classes.

How does aTyr compare?

Granted US patents 2015–2025 versus the largest corporate holders — this company marked ◀

patents

What this shows aTyr holds 82 patents — placing it at rank #4,364 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.

Source USPTO PatentsView — granted utility patents As of 2015–2025

USPTO utility patent grants by year · 2015–2025

0510152025 20152016201720182019202020212022202320242025 1
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
aTyr Pharma, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 21 25.6%
2016 15 18.3%
2017 19 23.2%
2018 8 9.8%
2019 6 7.3%
2020 5 6.1%
2021 3 3.7%
2022 1 1.2%
2023 2 2.4%
2024 1 1.2%
2025 1 1.2%

Patent Moat Analysis

Portfolio Volume Light
Tech Breadth Focused
Claim Depth Standard
Velocity Declining

Where it ranks

Overall rank by patents

#4,364

Across all tracked assignees

Innovation Score

36.5 out of 100

View all rankings →

Data Source

USPTO PatentsView — US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does aTyr Pharma, Inc. hold?
aTyr Pharma, Inc. holds 82 US granted patents filed between 2015 and 2025, spanning 10 technology areas.
What is aTyr Pharma, Inc.'s Innovation Score?
aTyr Pharma, Inc. has an Innovation Score of 36.5 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does aTyr Pharma, Inc. focus on?
aTyr Pharma, Inc.'s top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 79 patents. The company has filed patents in 10 CPC subclasses total.
Is aTyr Pharma, Inc.'s patent filing rate increasing or decreasing?
aTyr Pharma, Inc.'s recent filing velocity is -81% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for aTyr Pharma, Inc.'s patents?
aTyr Pharma, Inc.'s patents average 13.6 claims each. This falls within the standard range, providing solid legal coverage.
How is the aTyr Pharma, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

Learn More

Explore the patent dataset

Data sourced from USPTO PatentsView — official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

All federal data sources used on this page
  • USPTO PatentsView — official U.S. Patent and Trademark Office bulk patent data. patentsview.org
  • USPTO Patent Application Information Retrieval (PAIR) — application status and file history. uspto.gov/patents/pair
  • USPTO Bulk Data Storage System — comprehensive patent text + claims dataset. bulkdata.uspto.gov
  • USPTO CPC Classification — Cooperative Patent Classification scheme for technology categorization. uspto.gov/cpc
  • SEC EDGAR — public filings cross-reference for assignee corporate entity matching. sec.gov/edgar
  • WIPO PATENTSCOPE — international patent context (related international filings). wipo.int/patentscope